Citi raised the firm’s price target on Ascendis Pharma (ASND) to $243 from $213 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Grants Warrants to Employees to Boost Engagement
- Positive Outlook for Ascendis Pharma Driven by Yorvipath’s Growing Adoption and Revenue Potential
- Ascendis Pharma assumed with an Overweight at Morgan Stanley
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch